Disrupting a Single RNA Modification Turns Cold Tumors Hot

University of Liege

Immunotherapy has transformed cancer treatment for some patients. For many others, it has not worked at all. The difference often comes down to a single distinction: whether the tumor is "hot" or "cold." Hot tumors are infiltrated by immune cells, particularly T cells, which can be unleashed by checkpoint inhibitor drugs. Cold tumors have found ways to hide from the immune system entirely. No amount of checkpoint inhibition helps if the immune system does not know the cancer is there.

A study from the University of Liege, recently accepted for publication in Nature Communications, describes an entirely different strategy for making cold tumors hot. Rather than trying to activate immune cells directly, the researchers disrupted the tumor's internal protein-production machinery, forcing cancer cells to betray their own presence.

The quality control system that keeps tumors invisible

Every cell produces proteins by reading genetic instructions and assembling amino acids in the correct sequence. This process depends on molecular adaptors called transfer RNAs (tRNAs), which carry amino acids to the ribosome and ensure proteins are built correctly. Chemical modifications on tRNAs fine-tune this process, and cancer cells exploit this precision to maintain stability and avoid generating the kind of molecular alarm signals that would attract immune attention.

The research team, led by Pierre Close, director of the Laboratory of Cancer Signaling at the GIGA Institute, identified a specific tRNA modification controlled by an enzyme complex called KEOPS as critical to this immune evasion strategy. When the modification was disrupted in melanoma cells, the consequences cascaded quickly.

Without the modification, ribosomes began making errors. Proteins folded incorrectly and accumulated inside the cell. This buildup of faulty proteins activated an innate immune sensor normally reserved for detecting viral infections. The cell, in effect, began broadcasting a distress signal that said: something is very wrong in here.

From distress signal to tumor rejection

The immune alarm triggered by misfolded protein accumulation attracted T cells to the tumor site. In preclinical models, blocking the KEOPS pathway transformed cold tumors, the kind that typically ignore immunotherapy completely, into hot tumors infiltrated by immune cells. Tumor growth slowed markedly.

Close described the mechanism as forcing tumors to reveal what they normally work hard to hide. The approach is conceptually distinct from existing immunotherapies. Checkpoint inhibitors release the brakes on immune cells that are already present at the tumor. CAR-T therapy engineers immune cells to recognize cancer. This strategy does neither. Instead, it makes the cancer cells themselves generate the signals that recruit immune attack in the first place.

First author Clea Dziagwa, a PhD candidate, noted that understanding how tRNAs influence immune evasion opens the possibility of intervening where conventional immunotherapies fail. If a tumor is cold because it has perfected its protein quality control, then breaking that control could be the key to making the tumor visible.

Where RNA biology meets cancer immunology

The study bridges two fields that have not traditionally overlapped much: RNA biology and tumor immunology. tRNA modifications are an established area of molecular biology research, but their connection to immune evasion is new. The finding suggests that the precision of protein production is not just a housekeeping function but an active defense mechanism that tumors use to avoid detection.

This opens a class of potential drug targets that has not been explored for immunotherapy purposes. If small molecules can be developed to inhibit KEOPS or related tRNA modification enzymes specifically in tumor cells, they could potentially be combined with existing checkpoint inhibitors to treat cancers that currently do not respond to immunotherapy.

Preclinical results, human questions

The work was conducted in preclinical models, primarily mouse melanoma. Whether the same mechanism operates in human tumors, and whether it can be targeted therapeutically without unacceptable toxicity, remains to be determined. tRNA modifications are not unique to cancer cells. Disrupting them systemically could affect protein production in healthy tissues, potentially causing side effects that would need to be carefully managed.

The study focused on melanoma, one of the cancer types most amenable to immunotherapy research. Whether the KEOPS pathway plays the same immune-evasion role in other cancer types, particularly the notoriously cold tumors like pancreatic and glioblastoma, is an open and important question.

The distance from preclinical observation to clinical treatment is long and littered with promising approaches that did not survive translation. Still, the conceptual advance here is genuine. If you cannot make the immune system find the tumor by boosting the immune system, perhaps you can make the tumor impossible to miss by breaking its camouflage from the inside.